REVIEW OF FIVE YEARS OF CLINICAL DATA ON THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PD-L1 EXPRESSION-NEGATIVE PATIENTS

Abstract

Pembrolizumab is a programmed cell death protein 1 inhibitor, which is approved for the treatment of metastatic non-small cell lung cancer (NSCLC). The combination of pembrolizumab and chemotherapy is the current standard of firstline treatment for metastatic NSCLC with any programmed death-ligand 1 (PD-L1) expression without an activating epidermal growth factor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene translocation.